Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,950,368
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.73
  • Price/Sales 4.30
  • Price/Cash Flow 12.98
  • Price/Book 5.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.62 +2.85%
on 05/29/18
124.99 -2.39%
on 05/21/18
-2.24 (-1.80%)
since 05/18/18
3-Month
118.62 +2.85%
on 05/29/18
133.47 -8.59%
on 03/19/18
-11.68 (-8.74%)
since 03/16/18
52-Week
118.62 +2.85%
on 05/29/18
148.32 -17.75%
on 01/17/18
-12.35 (-9.19%)
since 06/16/17

Most Recent Stories

More News
FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio

Johnson & Johnson Vision announced today the U.S. Food and Drug Administration (FDA) approval of the iDESIGN Refractive Studio, making it the only system to use topography-integrated, wavefront-guided...

JNJ : 122.00 (-0.50%)
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright

OFIX : 59.00 (+0.63%)
SYK : 168.38 (-0.22%)
OSUR : 17.88 (+0.06%)
HSIC : 73.20 (-0.12%)
VAR : 122.17 (-0.92%)
BSX : 32.65 (-0.94%)
ABMD : 443.58 (+0.66%)
NXTM : 28.36 (-0.42%)
JNJ : 122.00 (-0.50%)
EGRX : 71.97 (-2.00%)
INSY : 8.15 (+1.24%)
MNK : 19.17 (unch)
TGTX : 12.90 (-5.80%)
ABT : 62.26 (-1.03%)
SRDX : 55.20 (-3.24%)
BAX : 74.76 (-0.61%)
MDT : 86.78 (+0.24%)
ISRG : 490.49 (-1.02%)
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

MYL : 38.88 (-0.31%)
JNJ : 122.00 (-0.50%)
PFE : 36.12 (-0.66%)
GSK : 41.04 (-0.97%)
Dow 30 Stock Roundup: Caterpillar Raises Dividend, Merck's Keytruda Gets FDA Nod

The Dow traversed a tough week, suffering losses for three consecutive sessions.

VZ : 47.89 (-0.35%)
JPM : 107.04 (-0.80%)
JNJ : 122.00 (-0.50%)
MRK : 61.50 (-0.85%)
CAT : 148.10 (-1.28%)
XOM : 80.30 (-0.45%)
PG : 77.05 (-0.43%)
DIS : 107.15 (-1.56%)
BA : 352.86 (-1.40%)
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

CVS : 69.96 (-0.19%)
CI : 175.05 (-0.16%)
JNJ : 122.00 (-0.50%)
BDX : 232.16 (-0.28%)
Kyros Law is Investigating Claims on Behalf of Invokana users: 1,100 Invokana Lawsuits Alleging Diabetic Ketoacidosis, Kidney Injury, Amputations and Heart Complications Filed.

Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking compensation for their injuries. According to...

JNJ : 122.00 (-0.50%)
Hillenbrand Announces New Head of Investor Relations

Hillenbrand, Inc. (NYSE: HI) announced that Richard A. Dudley has been appointed as its new leader of investor relations.

HI : 46.15 (-0.75%)
JNJ : 122.00 (-0.50%)
Growth & Income Buys | Johnson & Johnson and International Paper

This week's video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ), and International Paper (IP).

JNJ : 122.00 (-0.50%)
IP : 54.15 (-2.31%)
Medical Device Industry Outlook - June 2018

Medical Device Industry Outlook - June 2018

CVS : 69.96 (-0.19%)
EW : 152.00 (-0.33%)
STE : 106.07 (-0.53%)
VAR : 122.17 (-0.92%)
CI : 175.05 (-0.16%)
BSX : 32.65 (-0.94%)
JNJ : 122.00 (-0.50%)
BDX : 232.16 (-0.28%)
BAX : 74.76 (-0.61%)
HAE : 91.50 (+0.41%)
XARELTO® (rivaroxaban) Associated with Significantly Reduced Time in Hospital and Decreased Costs Compared to Standard of Care in New Study of Patients with Low-Risk Pulmonary Embolism (PE)

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the MERCURY PE study, which showed that people with low-risk pulmonary embolism (PE) treated with XARELTO® (rivaroxaban)...

JNJ : 122.00 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 123.68
1st Resistance Point 123.15
Last Price 122.00
1st Support Level 121.66
2nd Support Level 120.70

See More

52-Week High 148.32
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
Last Price 122.00
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar